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 Abstract. 
Intracellular cAMP levels are regulated by cAMP synthesis and degradation rate. Nine 
isoforms of cAMP-synthesizing enzymes called adenylyl-cyclases (ACs) and eleven 
phosphodiesterases (PDEs) that degrade cyclic nucleotides have been identified. Both 
types of enzymes exhibit variations not only in their expression pattern distribution 
throughout the brain, but also in their regulatory characteristics. Different isoforms of ACs 
and PDEs may be co-expressed in a single cell, thus a gradient of cAMP intracellular 
levels is formed, which accounts for the diversity of cell responses. Among these isoforms, 
AC5 and PDE7B are highly expressed in striatum, where the cAMP pathway is implicated 
in diverse behavioural functions. Striatal AC5 is involved in drug reinforcing actions and 
motor activity. Less is known about the role of the PDE7B isoenzyme.  We performed a 
double in situ hybridization analysis of the co-expression patterns of AC5 and PDE7B with 
µ-opioid-receptor, D1- and D2-receptor mRNAs to contribute to a better understanding in 
the regulation of cAMP levels under dopamine or opioidergic pathway activation in 
striatum. We found co-expression of AC5 and PDE7B mRNAs in caudate-putamen and 
nucleus accumbens; we also encountered that more than 50% of MOR, D2- and D1-
expressing cells contained AC5 and PDE7B mRNAs. The presence of AC5 and PDE7B 
mRNAs in D1- and D2-containing cells suggests the participation of these enzymes in 
striatal functions involving dopaminergic pathways. Co-localization of both isoenzyme 
mRNAs with MOR expressing cells suggests their involvement in opioid reinforcing effects.  
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 Abbreviations. 
AC adenylyl cyclase 
cAMP cyclic adenosine monophosphate 
dATP desoxy adenosine triphosphate 
DA  dopamine 
D1  dopamine 1 receptor 
D2  dopamine 2 receptor 
KO  knock-out 
MOR  μ-opioid receptor 
mRNA messenger ribonucleic acid 
MSN  medium spiny neurons 
NTR  neurotransmitter receptor 
PDE phosphodiesterase 
PKA protein kinase A 
SN   substantia nigra 
VTA ventral tegmental area 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction. 
 
cAMP signalling cascades are involved in a wide variety of cellular responses. Cyclic 
nucleotide levels are tightly regulated by cAMP synthesis and degradation rate. Adenylyl 
cyclases (ACs) are membrane-bound enzymes responsible for the formation of cAMP 
(Houslay et al. 1997), while phosphodiesterases (PDE) are hydrolyzing enzymes that 
convert cyclic nucleotides (3’, 5’-cyclic nucleotides) into the biological inactive 5’-
nucleoside monophosphate. There are ten mammalian AC isoforms (nine transmembrane 
and one soluble form) (Defer et al. 2000, Hanoune et al. 2001) and 11 PDE families with 
approximately 50 isoforms (Conti et al. 1999, Houslay et al. 1997). Different isoforms of 
ACs and PDEs may be co-expressed in a single cell to yield the differential regulatory 
properties of each isoform. As a result, a gradient of cAMP intracellular levels is originated 
that accounts for the diversity of cellular responses. Moreover, the specific set of ACs and 
PDEs isoforms ensures unique responses of different cells to the same stimulus. The 
analysis of the cellular and sub-cellular expression patterns of specific ACs and PDEs 
could provide further insight not only in the regulation of cAMP levels but in its functional 
roles as well. 
In brain, cAMP levels have been implicated in genetic transcription processes (Lalli et al. 
1994), ionic channel activation, dopaminergic neuron survival (Yamashita et al. 1997), 
synaptic plasticity (Zhong et al. 1991), neurotransmitter release (Bouron et al. 1999, Chen 
et al. 1997, Kandel et al. 1982), locomotion, sensory perception, as well as in memory and 
learning processes (Frey et al. 1993, Tully et al. 2003). 
In striatal cells, the increase in cAMP levels leads to activation of protein kinase A (PKA) 
which plays a role in reward mechanisms of drug consumption, locomotion activation and 
anxiety (Kim et al. 2008). The striatum contains dopaminergic terminals which receive 
information from the ventral tegmental area (VTA); 80% of the cells in this structure are 
medium spiny neurons (MSN) (Coskran et al. 2006, Seeger et al. 2003) containing 
dopamine 1 (D1) or dopamine 2 (D2) receptors. Striatal cells -integrators of dopaminergic 
signalling from VTA, substantia nigra (SN), as well as from cortical and thalamic afferent 
messages- are capable of regulating motor, sensory or cognitive action patterns. Thus, the 
control of the cAMP/protein kinase A (PKA) pathway is very strict and its impairment could 
be responsible for the development of psychotic processes, neurological alterations such 
as Parkinson’s and Alzheimer’s diseases and anxiety-related disorders. 
D1 receptor activation enhances cAMP levels while D2 activation causes a decrease by 
their coupling to a Gs or Gi protein G to produce positive or negative adenylyl cyclase 
activity, respectively.  Some AC activities and expression have been identified in striatum 
(AC1, AC5, AC8, AC9), being AC5 the most abundant in that brain region (Glatt et al. 
1993, Matsuoka et al. 1997). AC5 is involved in almost all the known functions regulated 
by the striatum: its expression is important although not essential for morphine effects after 
μ-opioid receptor (MOR) activation, which supports its role in drug-preference behaviour 
(Kim et al. 2006). Besides, AC5 has been proposed as the key AC activity of striatum for 
the dopamine effects on locomotion induced by D2 receptor agonists, but not by those of 
D1 (Lee et al. 2002). In ventral striatum (nucleus accumbens), AC5 has been implicated in 
the anxiety behaviour displayed by animals as a response to stressful stimuli (Kim et al. 
2008). Efforts have been made to involve AC5 in behaviours controlled by striatum in 
studies performed with AC5-/- KO animals, to assay its main role in the locomotion 
produced by drug addiction. However, it is also possible that the enhancement of other AC 
activities, that exert a compensatory effect due to the lack of AC5 expression in those 
animals, has provided false negative results concerning AC5 participation in some striatal 
processes. Also, since AC5 specific inhibitors are lacking, its participation in different 
striatal functions is not conclusive. 
 
Reinforcement of drug action and locomotion activation are two functional processes 
regulated by striatum which are at least in part modulated by the opioidergic system. 
Ethanol-induced DA release activation in striatum seems to involve µ opioid receptors 
(MORs), which are highly expressed in this region (Koob 1992). MORs are negatively 
coupled to AC activity and their activation has been related to the stimulation of the 
dopaminergic pathway (Nestler 2004). However, it has not yet been defined which AC 
activities and mRNAs are expressed in cells containing MOR, D1 or D2 receptors, that 
would contribute to clarify the role of enzymes AC5 and PDE7B in the regulation of cAMP 
levels in addictive behaviour, locomotion activation by drugs, or cognitive processes. 
Given that striatal cells receive diverse afferent signals, they need to integrate and 
discriminate them to trigger a specific cell response; thus, neurons may be responding to a 
stimulus and at the same time they must be prepared for a subsequent input. Presence of 
different sets of synthesizing and degrading ACs and PDEs in striatal cells ensures 
versatile response patterns to the afferent stimuli. If an incoming signal activates an AC 
enzyme enhancing cAMP levels, PDEs in striatal cells may contribute to the feedback 
mechanisms that maintain cAMP content at basal levels. Among the PDEs expressed in 
striatum (Menniti et al. 2006) (PDE1B, PDE4, PDE7B, PDE10A), PDE7B is an isoenzyme 
of the PDE7 family that has another member, PDE7A, also expressed in the basal ganglia, 
although not in the nucleus accumbens, where PDE7B is abundant (Reyes-Irisarri et al. 
2005). While PDE7A has been involved in immune cell responses (Yang et al. 2003), 
PDE7B has been implicated in dopamine signaling: the addition of a DA agonist to striatal 
cells enhances PDE7B expression (Sasaki et al. 2004). Among the phosphodiesterases 
expressed in striatum, PDE7B is the single-substrate degrading PDE with the highest 
affinity for cAMP; thus, it could be regulating cyclic nucleotide levels at basal conditions 
(Menniti et al. 2006).  
Striatal cells have a differential localization and expression of PDEs. In fact, the 
participation of these enzymes in motor and cognitive functions might be due to the 
specific PDE involved. Since the use of PDE7B specific inhibitors has not yet been 
possible, the identification of PDE7B sub-cellular distribution in striatum by the analysis of 
the phenotype of its expressing-cells (and its proportion in every cell population) could 
help to understand regulatory processes involved and to identify the controlling factors 
associated with PDE activities and expression. It would also contribute to the design of 
specific pharmacological agents for the treatment of different disorders, minimizing 
secondary effects of PDE inhibition.     
 
Despite the high striatal expression levels of AC5 and PDE7B, co-localization studies of 
their mRNAs with MOR and dopamine receptors are lacking. Therefore, the aim of this 
study is to analyze the cellular phenotype of AC5 and PDE7B expressing-cells in striatum 
by double in situ hybridization histochemistry for both enzyme mRNA expressions, to 
obtain information on the co-localization of the above mentioned neurotransmitter 
receptors with these particular enzymes, as well as their potential participation in different 
basal ganglia functions and the possible regulatory characteristics of the cAMP pathways 
in which AC5 and PDE7B might be participating.  
 
Results. 
Using double in situ hybridization histochemistry, we performed co-localization analysis of 
mRNAs coding for different neurotransmitter receptors (NTRs) viz., MOR (Fig 1A), D1 (Fig 
1D), and D2 (Fig 1G), with those of cAMP level-regulating enzymes particularly enriched in 
striatum, such as phosphodiesterase type 7B (PDE7B) (Fig 1J) (Reyes-Irisarri et al. 2005) 
and adenylcyclase type 5 (AC5) (Fig 1K) (Sanabra and Mengod, unpublished data and 
(Matsuoka et al. 1997)).   
Autoradiographic signals showed specific hybridization patterns for μ-opioid, D1 and D2, 
receptors and PDE7B in striatum, as it has been described elsewhere (Mansour et al. 
1994, Mengod et al. 1989, Mengod et al. 1991, Reyes-Irisarri et al. 2005) (Fig 1A, D, G, J), 
supporting the selectivity of the probes used. 
MOR signal was predominant in the dorsal part of striatum (Fig 1A); several MOR 
expressing-neurons contained AC5 (Fig 1B, Table 1) or PDE7B mRNA at similar 
proportions (F(2,18)= 0.189, p>0.05) (Fig 1C, Table 1). The number of cells expressing 
MOR/AC5 or MOR/PDE7B mRNAs did not vary between antero-posterior striatal levels 
(F(2,7)= 0.254, p>0.05; F(2,8)= 0.017, p>0.05, respectively). We observed a similar 
distribution in nucleus accumbens cells containing simultaneously MOR and AC5 mRNAs 
or MOR/PDE7B (F(1,4)= 4.45, p>0.05) (Table 1). 
A larger extent of caudate neurons (64 ± 0.6%) contained simultaneously MOR and AC5 
mRNAs than in n. accumbens (53 ± 8%) (Table 3) (F(1,13)= 8.34, p<0.05); while caudate vs 
n. accumbens distribution of MOR/PDE7B cells was similar (F(1,5)= 3.6, p>0.05) (Table 1). 
 
We counted twice the cells expressing simultaneously AC5 and PDE7B mRNAs. The first 
time, single digoxigenin labeled cells containing AC5 mRNA were taken as 100%; next we 
looked for all AC5 positive cells co-expressing PDE7B mRNA. The second time, we 
counted the radioactively labeled cells containing PDE7B and took this cell population as 
100%; subsequently, we found that 65% of PDE7B-expressing cells contained AC5 mRNA 
(Fig 1L, Table 2).  
A similarly high extent of D1 positive neurons expressing AC5 or PDE7B mRNAs in 
caudate was observed (F(2,21)= 0.068, p>0.05) (Fig 1E,F; Table 1), with no difference 
between rostral and caudal striatum (AC5: F(2,9)= 1.71, p>0.05; PDE7B: F(2,9)= 2.27, 
p>0.05). We found a different distribution extent of D1/AC5 cells between dorsal and 
ventral striatum (F(1,18)= 7,265, p<0.05) (Table 1) while the D1/PDE7B population was 
similar between both areas (F(1,18)= 0,713, p>0.05). Although the percentage of D1/AC5 or 
D1/PDE7B co-expressing cells was similar among the three caudate section levels, 
nucleus accumbens presented differences (D1/AC5 (72%) vs D1/PDE7B extent (83%)): 
(F(1,14)= 23,66, p<0.001). 
Many of the D2 cells expressed AC5 or PDE7B mRNA in a similar extent (F(2,18)= 0.32, 
p>0.05) (Fig 2H, I; Table 1); no difference was found between rostral and caudal striatum 
(D2/AC5: F(2,9)= 3.57, p>0.05; D2/PDE7B: F(2,7)= 2.59, p>0.05). In contrast, there were 
differences between dorsal and ventral distribution of D2/AC5 (F(1,18)= 19,061, p<0.001) 
and D2/PDE7B (F(1,16)= 23,737, p>0.001). The percentage of D2/AC5 and D2/PDE7B cells 
in nucleus accumbens was similar (Table 1). 
Regarding AC5 or PDE7B positive cells as 100%, the extent of neurons co-expressing 
AC5/D1 and PDE7B/D1 was the highest (59, and 58% respectively) and similar to the 
percentage of AC5/MOR and PDE7B/MOR neurons, supporting the expression of these 
four mRNAs in a high proportion in striatal neurons. AC5/D2 and PDE7B/D2 cells were 
present in a lower extent (Table 3).  
Discussion. 
 
Regulation of cAMP levels plays a key role for striatum-controlled functions such as 
movement behaviour and drug reinforcement effects. Opioid or ethanol repeated 
administration enhances cAMP, CREB and PKA levels and phosphorylated factors as 
targets for CREB (Koob 1992, Nestler 2004). These increased cAMP levels have been 
related to behavioural changes induced by drugs, such as aversive state of animals during 
drug withdrawal (Nestler et al. 1997), as well as drug tolerance, dependence and reward 
mechanisms.  
Locomotion is another behaviour altered by drugs (Barrot et al. 2002, Nestler 2004) and 
regulated by striatal pathways. This process includes D1 receptor activation by 
psychostimulant administration, as well as increased cAMP levels in striatum. Thus, 
enzymes regulating cAMP levels in the striatum are highly important given the variety of 
drug mechanisms and neurodegenerative processes that depend on dopamine effects for 
the tuning of cyclic nucleotide content. Among those cAMP synthesizing enzymes 
expressed in striatum, AC5 is the most abundant. Efforts have been made to relate the 
activity of this enzyme to striatum-controlled functions, as well as to different behaviours 
triggered by D1- and D2-receptor activation (Kim et al. 2008, Kim et al. 2006, Lee et al. 
2002).  
Dopamine released in the striatum acts on medium spiny neurons containing D1 and D2 
receptors, to produce an integrated behavioural response of animals to dopamine tone. D2 
agonist administration in striatum is able to reduce increased AC activity provoked by D1-
stimulation. The importance of AC5 for the balance of these two D1 and D2 regulated 
pathways in the control of locomotion is evidenced in studies with AC5-/- KO mice, in which 
the D2-Gαi-AC system is dependent on AC5 activity to trigger the behavioural response 
induced by dopamine agonists; in contrast, for D1 receptors, AC5 seems to be important, 
but the locomotion displayed by animals also needs of other non AC5 factors (Lee et al. 
2002). 
Besides the dopamine system, the opioidergic pathway is relevant to drug tolerance and 
dependence, as well as to reward processes of addiction controlled by striatum (Koob 
1992).  Dopamine release in striatum affects the opioidergic system directly and induces 
the characteristic behaviours of drug addiction. AC5 activity has also been involved in the 
locomotion activation due to morphine administration. In AC5-/- KO mice, morphine and 
MOR agonists induce a slighter decrease in striatal AC activity after forskolin 
administration and weaker, though not blocked effects on locomotion and drug preference 
than wild type animals (Kim et al. 2006). This suggests that AC5 is important but not 
essential for MOR activation. 
In this study, we analyzed whether D1, D2 and MOR receptors are co-expressed with 
AC5, a cAMP-synthesizing enzyme, and PDE7B, a degrading one. We were also 
interested in the proportion of striatal receptor-containing cells expressing AC5 and 
PDE7B mRNAs. By understanding the regulatory characteristics of each enzyme and its 
predominance in specific striatal cells, our results could provide further insight into cAMP-
pathway regulation in striatum as the key to the diverse behavioural functions controlled by 
this region. It could also help in the determination of the potential role of AC5 and PDE7B 
activities in drug-related locomotion and reward mechanisms. Furthermore, it could enable 
the design of specific inhibitors of these enzymes as therapeutic agents to pathologies 
related to impaired processes controlled by striatum.  
Our results showing more than 50% of MOR positive cells co-expressing AC5 mRNA are 
in agreement with previous studies that suggest AC5 as the main AC activity involved in 
morphine behavioural changes through MORs (Kim et al. 2006). Other enzymes such as 
AC1, AC8 or AC9, also expressed in striatum, may account for residual behavioral effects 
and AC activity of AC5-/- KO animals after morphine administration (Kim et al. 2006). This 
evidence indicates that each enzyme regulates cAMP levels in a stimulus-specific manner. 
A high percentage of D1 expressing cells exhibited AC5 mRNA. Given that more caudate-
putamen neurons co-expressed D1/AC5 than MOR/AC5 mRNAs (80 vs 64%), it is 
possible that some D1-mRNA-containing cells express simultaneously AC5 and MOR 
receptors (McGinty et al. 1998).  
 
We observed co-localization of AC5 with D2 mRNAs; this finding suggests a role for D2 
agonists in locomotion, after DA agonist administration through AC5 activation identified in 
AC5-/- KO animals (Lee et al. 2002). Given the higher percentage of D2/AC5 containing 
cells than that of MOR/AC5, it is likely that D2/AC5 mRNAs-containing cells are also 
expressing MORs. This hypothesis could explain the blocked opioid effect on locomotion 
after morphine administration in AC5-/- KO animals (Lee et al. 2002). 
The presence of AC5 in both types of medium spiny neurons may account for the D1 and 
D2 receptor activation induced by dopamine release participating in the control of 
locomotion. The higher proportion of D1 and D2 containing cells expressing AC5 may be 
important for the different cAMP concentrations needed for the diverse behavioural 
responses displayed by animals after drug administration. Thus, the identification of the 
phenotype of AC5 expressing cells would be relevant for the design of specific inhibitors 
with potential use as therapeutic agents in drug addiction.  
 
In nucleus accumbens we found co-localization of AC5 mRNA with D1 and D2 containing 
cells. In the mesolimbic pathway, dopamine signaling through D1 receptors increases 
cAMP levels, when animals are subjected to stressful conditions. Furthermore, activation 
of the cAMP pathway has been associated with the anxiety behavior displayed by these 
animals. Since AC5-/- KO mice have an anxiolytic phenotype and higher locomotor and 
exploring activities; AC5 seems to be the main enzyme implicated in this behaviour. Our 
results here provide further support for AC5 involvement in reward mechanisms, as well as 
in mood disorders controlled by nucleus accumbens (Kim et al. 2008) in animals subjected 
to stress stimuli. Synthesis of other peptides with anxiety-related actions in nucleus 
accumbens, such as cholecystoquinin (CCK) and dynorphin seems to depend on AC5 
activity (Kim et al. 2008). Again, as for dorsal striatum, AC5 may be participating in the 
balanced response of D1 and D2 containing cells to dopamine and opioid release, as well 
as, to the feedback regulation of dopaminergic cells in the VTA. 
 
PDE7B is a cAMP degrading enzyme markedly expressed in the striatum with a high 
degree of specificity for its substrate. Its distribution in medium spiny neurons has been 
analyzed (Reyes-Irisarri et al. 2005), but the phenotype of the PDE7B containing cells has 
not been identified. We found here that PDE7B mRNA co-localizes with both D2 and D1 
containing neurons in striatum and nucleus accumbens. Since PDE7B mRNA levels are 
enhanced after D1 agonist administration (Sasaki et al. 2004), it seems that PDE7B 
activity may return cAMP to basal levels after its increase due to an enhanced AC activity 
(by D1); this would allow cells to be prepared for the next stimulus. Specific inhibitors of 
PDE7B may counteract D2 receptor activation, which would in turn potentiate D1 receptor 
activity, thus participating in the motor control by striatum.  PDE7B is known to be absent 
in dopaminergic cells from the SN and VTA (Reyes-Irisarri et al. 2005) that express D2 
with an autorreceptor function. Thus, PDE7B mRNA could be a marker for D2 
striatopallidal neurons. Although the former results suggest the non participation of PDE7B 
in DA release control, it is possible that its activity is involved in DA synthesis and release 
through the feedback loop of the MSN to SN and VTA, when the dopaminergic tone is 
increased in striatum. 
The low Km of PDE7B for cAMP levels suggests its importance in maintaining cAMP 
levels in basal conditions, which is relevant for the tonic activation of D2-containing 
neurons. PDE7B expression in both D1- and D2-expressing striatal neurons suggests its 
participation in the integrated response of locomotion that depends on the activation of 
both types of cells.  
In this respect, co-localization of PDE7B with D2 containing cells suggests that PDE7B 
specific inhibitors may exert antipsychotic actions and modulate hyperlocomotion induced 
by psychostimulants, since inhibiting PDE7B could enhance cAMP levels and counteract 
D2 receptor activation, as has been proved for other PDEs expressed in striatum, such as 
PDE10A (Weber et al. 2009). Also, since PDE7B is constitutively expressed, its activity 
may account for the tonic activity of the D2-expressing cells in the striatum. However, 
PDE7B has cAMP as unique substrate in contrast to other phosphodiesterases localized 
also in striatum, such as PDE10A (this enzyme also degrades cGMP). This characteristic 
is relevant for the potential counteracting effects of PDE7B inhibitors on D2 activation as 
therapy for psychosis.  
Dopamine has been involved in striatal cell differentiation in rat embryonic cultures  
through D1 receptor activation (Schmidt et al. 1998); since PDE7B is co-localized with D1 
receptors and D1 agonists increase PDE7B expression, it is not unlikely its participation in 
that cellular process.  
Its co-localization with these DA receptors in nucleus accumbens and at the same time 
with AC5 mRNA, points towards PDE7B as a target for the control of anxiety behaviours 
involving AC5 activation.  Also, since low cAMP levels in nucleus accumbens have been 
related to the pre-pulse deficiency (PPI) of the startle reaction (Weber et al. 2009), which 
is considered a behavioural characteristic of schizophrenia appearing in postpartum rats, 
PDE7B may be a target for the control of this mental illness (Byrnes et al. 2007).   
It would be helpful to develop PDE7B inhibitors, since those available that target other 
PDE activities induce some side effects such as emesis and cardiotoxicity (Barnes et al. 
2001).  
 
The presence of PDE7B mRNA in MOR, D1 and D2 expressing cells, together with the 
observation that all AC5-expressing cells also contain PDE7B mRNA, suggests that all 
MOR, D1 and D2 positive cells containing AC5 mRNA simultaneously express PDE7B. 
Thus, PDE7B activity may induce compensating increments of cAMP levels and prepare 
neurons for a subsequent stimulus after D1 activation. In addition, its constitutive 
expression (Sasaki et al. 2004) PDE7B may contribute to maintain low cAMP levels in 
MOR expressing cells, as well as may be in part responsible for the locomotor activation 
and drug preference induced by morphine. 
Its co-localization with MOR in nucleus accumbens indicates that regulation of PDE7B 
activity may be important for therapy (control) of drug addiction, since increased cAMP 
levels has been associated with the negative motivational state during drug withdrawal.  
 
The observation of cells co-expressing AC5 and PDE7B enzymes may help to identify 
their roles as regulating enzymes of cAMP content and their participation in specific striatal 
functions. Their co-expression in both dorsal striatum and nucleus accumbens suggests 
that these enzymes may be controlling cAMP levels and in turn CREB phosphorylation 
among other functions, as well as transcription of opioid peptide genes that are expressed 
in both striato-nigral (dynorphin) and striato-pallidal (proenkephalin) cells, which participate 
in long-term neural and behavioral plasticity in response to drugs. Also, the co-expression 
of PDE7B and AC5 indicates their possible participation in drug reinforcement 
mechanisms controlled by VTA neurons, by the activation of the VTA or SN firing rate 
within the long-loop feedback that includes direct and indirect pathways. 
 
 
Experimental Procedure.   
 
Tissue preparation  
Male Wistar rats averaging 250g in body weight (n=4) were kept in an animal house under 
controlled light and temperature conditions until they were sacrificed by decapitation. 
Brains were immediately extracted and frozen on dry ice. Striatal coronal slices (14 µm 
thick) were obtained by cutting brains with a microtome-cryostat (Microm HM500 OM, 
Walldorf, Germany) at -20 C and thaw-mounted onto APTS-coated (3-
aminopropylyltriethoxysilane; Sigma, St. Louis Mo, USA) slides. Selected sections were 
located at 1.7, 1, and -0.8 mm coordinates from Bregma (Paxinos G, Watson C. 1998). 
 
Hybridization probes 
Oligonucleotides used in this study were complementary to the following base sequences 
(GenBank Acc. No. inside brackets): AC5, bases 3061-3105, 3172-3216, and 3116-3160 
(NM 022600); PDE7B, bases 2233-2247, 556-600, 1390-1434, 190-234, and 496-540  
(NM 080894); μ-opioid receptor, bases 187-231, 1431-1475, 803-850, and 1279-1323 
(NM 013071); D1 receptor, bases 752-796 (NM 012546); D2 receptor bases 347-388 (NM 
012547). All oligonucleotides were synthesized and HPLC purified by Isogen Bioscience 
BV (Maarsden, The Netherlands). Evaluation of oligonucleotide sequences with basic local 
alignment search tool (BLAST) of EMBL and GenBank databases indicated that probes 
showed no significant similarities with mRNAs others than their corresponding targets in 
the rat.  
Oligonucleotide probes for AC5 and PDE7B were independently labeled with digoxigenin, 
whereas those for receptors were radiolabeled, except for Figure 1J, in which the PDE7B 
hybridization signal is radioactive. Oligonucleotides were radioactively labeled at their 3’-
end using [ -33P]dATP (3000 Ci/mmol;New England Nuclear, Boston, MA, USA) for in situ 
hybridization histochemistry experiments; terminal deoxynucleotidyltransferase (Oncogene 
Research Products, San Diego, CA, USA) was purified using QIA quick Nucleotide 
Removal Kit (Qiagen GmbH, Hilden, Germany (Tomiyama et al. 1997). Oligonucleotides 
were non-radioactively labeled with the same enzyme, Dig-11-dUTP (Roche Diagnostics 
GmbH, Mannheim, Germany), in accordance with previous described procedures (Schmitz 
et al. 1991). 
 
In situ hybridization histochemistry procedures. 
Procedures followed for radioactive and non-radioactive labeling of oligonucleotides and 
for in situ hybridization experiments have been published elsewhere (Reyes-Irisarri et al. 
2005, Serrats et al. 2003). Briefly, frozen tissue sections were thawed, fixed for 20 min at 
4ºC in 4% paraformaldehyde in phosphate-buffered saline (PBS; 1X PBS: 8 mM 
Na2HPO4, 1.4 mM KH2PO4, 136 mM NaCl, 2.6 mM KCl), washed for 5 min in 3X PBS at 
room temperature, twice for 5 min/each in 1X PBS, and incubated for 2 min at 21ºC in a 
pre-digested pronase solution (incubated at 37ºC for 4hr and kept frozen in aliquots) 
(Calbiochem, San Diego, CA, USA) at a final concentration of 24 U/ml in 50 mM Tris-HCl 
pH 7.5, 5 mM EDTA. Enzymatic activity was stopped by immersion in 2 mg/ml glycine in 
1X PBS for 30s. Tissues were finally rinsed in 1X PBS and dehydrated through a graded 
ethanol series. Radioactively labeled and non-radioactively labeled probes were diluted in 
a solution containing 50% formamide, 4X SSC (1X SSC: 150 mM NaCl, 15 mM sodium 
citrate), 1X Denhardt’s solution (0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine 
serum albumin), 10% dextran sulfate, 1% sarkosyl, 20mM phosphate buffer pH 7.0, 250 
µg/ml yeast tRNA and 500 µg/ml salmon sperm DNA. Final concentrations of radioactive 
and Dig-labeled probes in hybridization buffer were in the same range (approximately 1.5 
nM). Tissue sections were covered with hybridization solution containing labeled probes, 
overlaid with Nescofilm coverslips (Bando Chemical Inc., Kobe, Japan) and incubated 
overnight at 42ºC in a humid chamber. Sections were washed four times (45 min/each) in 
0.6 M NaCl, 10 mM Tris-HCl pH 7.5 at 60ºC, followed by a final 30 min wash in the same 
buffer at room temperature.  
 
Development of radioactive and non-radioactive hybridization signal. 
Hybridized sections were treated as described elsewhere (Landry et al. 2000). Briefly, 
after washing, slides were immersed for 30 min in a buffer containing 0.1M Tris-HCl pH 
7.5, 1M NaCl, 2mM MgCl2 and 0.5% bovine serum albumin (Sigma) and incubated 
overnight at 4ºC in the same solution with alkaline-phosphatase-conjugated anti-
digoxigenin-F(ab) fragments (1:5000; Roche Diagnostics GmbH). Subsequently, slides 
were washed three times (10 min/each) in the same buffer (without antibody), and twice in 
an alkaline buffer containing 0.1 M Tris-HCl pH 9.5, 0.1 M NaCl, and 5 mM MgCl2. Alkaline 
phosphatase activity was developed by incubating sections with 3.3 mg nitroblue 
tetrazolium and 1.65 mg bromochloroindolyl phosphate (Roche Diagnostics GmbH) diluted 
in 10 ml of alkaline buffer. The enzymatic reaction was blocked by extensive rinsing in the 
alkaline buffer containing 1 mM EDTA. Sections were then briefly dipped in 70% and 
100% ethanol, air-dried, dipped in cholodion and then into Ilford K5 nuclear emulsion 
(Ilford, Mobberly, Chesire, UK) diluted 1:1 with distilled water. They were exposed in the 
dark at 4ºC for two weeks for the double-labeled experiment of AC5/PDE7B, and for 4 
weeks for the rest of the experiments, and finally developed in Kodak D19 (Kodak, 
Rochester, NY, USA) for 5 min, and fixed in Ilford Hypam fixer (Ilford). For film 
autoradiography, hybridized sections were exposed to Biomax-MR (Kodak) films for 3 
days at -70ºC.  
 
Several routine controls were carried out to determine the specificity of the hybridization 
signals. As we have previously described (Pompeiano et al. 1992, Reyes-Irisarri et al. 
2005), for each of the mRNAs under study, several oligonucleotide probes complementary 
to different regions of the same mRNA were independently used as hybridization probes in 
consecutive tissue sections showing identical hybridization patterns. For a given 
oligonucleotide probe, addition in the hybridization solution of an excess of the same 
unlabeled oligonucleotide resulted in the complete abolition of the specific hybridization 
signal. The remaining autoradiographic signal was considered background. If the 
unlabeled oligonucleotide included in the hybridization solution corresponded to a different 
oligonucleotide, then the hybridization signal was not affected. The thermal stability of the 
hybrids was examined by washing at increasing temperatures: a sharp decrease in the 
hybridization signal was observed at a temperature consistent with the Tm of the hybrids 
(data not shown). 
 
Analysis of the results. 
AC5 or PDE7B mRNA-containing cells were identified as cellular profiles exhibiting a 
coloured precipitate (alkaline phosphatase reaction product) surrounding or covering the 
nucleus, clearly distinguishable from the background. MOR, D1 or D2 receptor mRNA 
hybridization signal was considered positive when accumulation of silver grains over the 
stained cellular profiles was greater than four times that of the background. Background 
was defined over those tissue areas negative for hybridization signal. Due to the presence 
of silver grains at different focal levels, a careful examination of each putatively positive 
cell was carried out under the microscope to validate positive signals. Cells were counted 
manually using an Axioplan microscope (Zeiss, Oberkochen, Germany) with a Darklite 
illuminator (Micro Video Instruments, Avon, MA, USA) that under dark-field provided a dim 
but enough light that allowed the visualization of both white silver grains and digoxigenin-
coloured cells.  
We analyzed 5 fields/side of each dorsal striatum (ten fields/section). Since we had three 
different locations (at coordinates of 1.7, 1 and -0.8mm) (Paxinos G, Watson C. 1998) 
sections/location, we examined a total of 60 fields/dorsal striatum/rat. Given that only two 
locations contained the nucleus accumbens, the total number of fields for this region was 
40 fields/rat. Dorsal striatum located at 1.7 and 1.0 mm was counted above an imaginary 
line drawn at 6 mm of vertical (V) coordinates (at the level of the base of the lateral 
ventricle) and below the corpus callosum which is easily recognizable. At the location 1.7 
mm, the positive cells of the nucleus accumbens were counted below the line mentioned 
(V 6 mm), lower limit at V 7.8, left lateral limit at 0.5 (or –0.5 for the left section), and right 
limit at 2.8 mm, being careful to examine only the area nearest to the anterior commissure. 
For the section at 1.00 mm, nucleus accumbens positive cells were counted inside the 
limits of an imaginary square figure: left limit L 0.8 mm (or –0.8 mm for the left side of the 
section), right limit 2.7 mm (or –2.7 mm), upper limit V 6.9 mm and lower limit V 7.8 mm. 
The section at –0.8 mm contained no nucleus accumbens; thus, dorsal striatum was 
exclusively examined.  We calculated the percentage of NTR-containing cells expressing 
AC5 or PDE7B (NTR cells were taken as 100%) and the percentage of AC5-expressing 
cells containing also PDE7B mRNA (AC5 positive cells were considered as 100%) in 
dorsal and ventral striatum. Also, we made a calculus of the extent of AC5 or PDE7B-
expressing cells (each one taken as 100%) that contained NTR mRNA in caudate-
putamen and nucleus accumbens. 
 
Preparation of the figures. 
Hybridized tissue section images from film autoradiograms were taken with a Wild 420 
Leica macroscope equipped with a digital camera (DXM1200 F, Nikon) and ACT-1 Nikon 
Software. Microphotographies of the hybridized tissue slides were performed using a Zeiss 
axioplan microscope equipped with a digital camera (DXM1200 F, Nikon) and ACT-1 
Nikon Software. Bright-field images were captured with transmitted light; dark-field images 
with a Darklite illuminator (Micro Video Instruments, Avon, MA, USA). Figures were 
prepared for publication using Adobe Photoshop Software (Adobe Software, San Jose, 
CA, USA). The contrast and brightness of images were the only variables adjusted 
digitally. For anatomical reference, sections close to those used were stained with cresyl 
violet.  
 
 
Statistical analysis. 
Student’s t-test was performed to compare the percentage of NTR-positive neurons 
expressing AC5 vs NTR-cells containing PDE7B mRNA, and caudate vs n.accumbens 
percentage of double-labeled cells; one-way ANOVA analysis was used to identify 
differences in the number of double-labeled cells between different brain section levels in 
each experiment (three for caudate and two for n.accumbens). Bonferroni’s post-hoc test 
was used when differences were significant (p<0.05). 
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TABLE 1. Expression of AC5 or PDE7B mRNAs in striatal cells containing MOR, D1, or 
D2 dopamine receptors. 
 AC5 PDE7B 
 Caudate- 
putamen 
Nucleus 
accumbens 
Caudate- 
putamen 
Nucleus 
accumbens 
                 MOR 64 ± 0.6 % 53 ± 8 % 68  ± 2 % 63  ± 0.1 % 
D1    80 ± 2  % 72 ± 2 % 81  ± 1 %   83  ± 2  % 
D2  65 ± 0.8 % 52 ± 3 %      67 ± 2 %   50  ± 1  % 
 
TABLE 2.Co-expression of AC5 and PDE7B mRNAs in striatal cells.  
 AC5 PDE7B 
AC5  99.6 ± 0.2 % 
PDE7B 65 ± 2 %  
 
 
 
TABLE 3. Expression of MOR, D1, or D2 receptor mRNAs in striatal cells containing AC5 
or PDE7B enzyme mRNAs. 
ENZYMES  MOR D1 D2 
AC5          50 ± 3 % 59  ± 2 % 42  ± 2 % 
PDE7B 56 ± 2 % 58  ± 1 % 41  ± 3 % 
 
 
 
Table 1. Expression of AC5 or PDE7B mRNAs in striatal cells containing MOR, D1, or D2 
dopamine receptors. Values (in percentage) are the mean ± S.E.M. of cells expressing 
MOR, D1, or D2 mRNA (taken as 100 %) simultaneously containing AC5 or PDE7B 
mRNAs in caudate-putamen or nucleus accumbens; values represent the mean of 
counted cells in an average of 10 fields/each striatum level/rat, n=4. The average number 
of counted cells expressing each enzyme mRNA was 20 ± 1/field for AC5 and 26 ± 2/ field 
for PDE7B.  
Table 2. Co-expression of AC5 and PDE7B mRNAs in striatal cells. Double labeled cells 
were counted twice. The first time, single digoxigenin labeled cells containing AC5 mRNA 
were taken as 100%, next we obtained the percentage of double labeled cells containing 
AC5 and PDE7B mRNAs. The second time, radioactively labeled cells expressing PDE7B 
were taken as 100%. In this manner, the values are either the mean ± S.E.M. of the 
percentage of AC5 positive cells (taken as 100%) or the percentage of the PDE7B mRNA 
containing cells that were double labeled (containing AC5 and PDE7B) in striatum. Values 
represent the mean of counted cells in an average of 10 fields/each striatum level/rat, n=4. 
The average number of counted cells expressing AC5 mRNA was 17 and 56 for PDE7B 
mRNA/field.  
Table 3. Expression of MOR, D1, or D2 receptor mRNAs in striatal cells containing AC5 or 
PDE7B enzyme mRNAs. Values are the mean ± S.E.M. of the percentage of cells 
expressing AC5 or PDE7B enzyme mRNAs (taken as 100 %) that simultaneously 
contained MOR, D1, or D2 mRNA in striatum; values represent the mean of counted cells 
in an average of 10 fields/each striatum level/rat, n=4.  
 Fig 1. Panels A, D, G, J, and K show autoradiographic signals of 33P-labelled MOR (A), D1 
(D), D2 (G), PDE7B (J), and AC5 (K) oligonucleotides from rat coronal striatal sections 
obtained by in situ hybridization histochemistry. Panels B, E, H are photomicrographs 
taken with a Darklite illuminator of emulsion dipped sections of the striatum showing 
simultaneous cellular localization of AC5 mRNA -using digoxigenin labeled 
oligonucleotides (dark precipitate)- and either 33P-MOR (B), D1 (E), D2 (H), or PDE7B (L) 
mRNA labels; or cellular localization of PDE7B mRNA labeled with digoxigenin in cells 
expressing MOR (C), D1 (F), or D2 mRNAs (I) radioactively labeled and detected by 
double in situ hybridization histochemistry. Double-labeled cells expressing two mRNAs 
are indicated by black and white arrows, while single radioactively-labeled cells are 
indicated by solid black arrows. Scale bar = 20 μm. 
 
